August 19th 2025
No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.
Treatment With Frontline, Continuous Ibrutinib Plus Rituximab Yields Better QOL in CLL
December 12th 2021Patients with chronic lymphocytic leukemia experienced improved quality of life after being treated with continuous ibrutinib and rituximab, as well as frontline fludarabine, cyclophosphamide, and rituximab.
FDA Approves Rituximab Plus Chemo for Select Pediatric Hematologic Malignancies
December 3rd 2021The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.
DNA Sequencing of Bone Marrow Is Predictive of ALL Relapse Following Treatment With Tisagenlecleucel
December 2nd 2021DNA sequencing to detect minimal residual disease and eventual relapse was more accurate than flow cytometry for adult and pediatric patients with acute lymphoblastic leukemia who have been treated with tisagenlecleucel.
Gemtuzumab Ozogamicin Plus Chemo Improves Outcomes in Pediatric KMT2A-Rearranged AML
December 1st 2021Pediatric patients with KMT2A-rearranged acute myeloid leukemia who were treated with gemtuzumab ozogamicin plus standard chemotherapy experienced improved event-free survival and a reduced relapsed risk.
Venetoclax Plus CLIA Regimen Improves Event-Free Survival and Overall Survival in AML and MDS
October 5th 2021Adding venetoclax to cladribine, high-dose cytarabine, and idarubicin appears to yield high rates of minimal residual disease negativity and promising survival in patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.